wiss pharma giant Roche (RHHBY) is buying the smaller U.S. biotech firm Ignyta (RXDX) for $1.7 billion in cash, picking up an experimental pill in the late stage of development that targets lung cancer caused by a rare gene defect.

Ignyta is being acquired for $27 per share, the companies said Friday. That’s a 74 percent premium to Ignyta’s closing price on Thursday. Roche aims to close the deal in the first half of 2018.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.